Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

arVax(TM). The objective of the Phase II study was to evaluate safety, tolerability and immunogenicity of SparVax(TM) and to compare it to the licensed vaccine, BioThrax(R), which was administered in accordance with the then approved vaccination route and regimen for general use in prophylaxis against anthrax. A total of 226 healthy male and female volunteers, age 18-55, were enrolled in the trial which was conducted at 16 sites in the United States.

The subjects were randomized to receive either three doses of BioThrax(R) or SparVax(TM) (at one of two dose levels followed by an antigenic challenge dose, i.e., a dose to show that the initial series of doses adequately "primed" the immune system to respond to natural infection by producing antibody due to immunologic memory.) The three dose groups were: 50 Microgram SparVax on Days 0, 28 and 56 (n = 91); 100 Microgram SparVax on Days 0, 28 and 56 (n = 92), and; 0.5 mL BioThrax(R) on Days 0, 14, and 28 (n = 43). At day 182, subjects receiving SparVax(TM) were re-randomized to a challenge at the original dose, on either day 182 or 364. The antigenic challenge dose (50 or 100 Microgram) each subject received was the same as the dose assigned to that subject during the initial vaccination schedule. Safety and immunogenicity were assessed throughout the study.

BioThrax(R) subjects were allowed to complete the full course of treatment, but data were not collected from these subjects after Day 70. Subjects who continued in the study were followed up for 18 months (Day 546) from the original vaccine dose.

Study results showed that there were an increased proportion of individuals experiencing injection site pain in the BioThrax(R) group as compared to the SparVax(TM) groups at both dose levels. There were no notable differences between the SparVax(TM) groups and the BioThrax(R) group regarding safety laboratory values, vital signs and ECG results. Additionally, in th
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 Cambridge ... solutions driven by Semantic Web technology, and ... information and services for the academic and scientific, ... its joint solution ‘Smart Data Lake for Clinical ... for the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... TORONTO , April 16, 2015 /PRNewswire/ - Portage ... PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce ... Investor Show on April 25, 2015 to be held ... Dr. Gregory Bailey and Mr. James ... overview and an update on the key programs at ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... a long-planned departure from its traditional focus, high-end computer ... U.S. Army for development of two different products. , ... it has secured $2.2 million in federal contracts for ... the Armys Research, Development and Engineering Command (CERDEC) to ...
... Inc. for the quarter ended March 31 rose to $142.5 ... company earned the same quarter of 2004. , ,Profit for ... even $150 million, compared to $78.3 million a year ago. ... more than $10 per share Tuesday and Wednesday from Monday's ...
... Milwaukee Merge eFilm , the Milwaukee-based ... Inc., continued to build momentum leading into its proposed ... net sales of just more than $10.5 million in ... first quarter 2004, after a 19 percent year-over-year jump ...
Cached Biology Technology:SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Merge eFilm earnings jump precedes planned merger 2Merge eFilm earnings jump precedes planned merger 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... controlled trial of fish oil given intravenously to patients ... exchange, reduces inflammatory chemicals and results in a shorter ... open access journal Critical Care investigated the ... solution for patients with sepsis, finding a significant series ...
... 1. Prescribed Opioids Associated with Significant Risk for ... oxycodone, have increased significantly over the past decade. As ... common, the deaths associated with opioids increase. Opioid overdose ... Researchers sought to determine the rate of opioid overdose ...
... MIT and Harvard Medical School have built targeted nanoparticles ... medicine, an advance that potentially provides an alternative to ... The particles, dubbed "nanoburrs" because they are coated with ... target proteins, can be designed to release their drug ...
Cached Biology News:Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 2Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 3New nanoparticles target cardiovascular disease 2
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... (M-MLV RT) is an RNA-dependent DNA polymerase that ... messenger RNA templates (>5kb). The enzyme is a ... consists of a single subunit with a molecular ... M-MLV RT is weaker than the commonly used ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... highly potent TURBO DNase (patent pending) in the ... in DNA removal capabilities. TURBO DNase is a ... much more efficient than wild type DNase I ... TURBO DNase binds DNA substrates 6-fold more tightly ...
Biology Products: